1289207-30-2

Usage

Uses

Used in Organic Synthesis:
4-bromo-1-methyl-1H-pyrrole-2-carbonitrile is used as a building block in organic synthesis for constructing more complex molecules. Its unique structure and reactivity allow for the creation of a wide range of compounds with diverse applications.
Used in Pharmaceutical Research:
In pharmaceutical research, 4-bromo-1-methyl-1H-pyrrole-2-carbonitrile is used as a starting material for the development of drugs targeting various medical conditions. Its chemical properties make it a valuable component in the design and synthesis of potential therapeutic agents.
Used in Drug Development:
4-bromo-1-methyl-1H-pyrrole-2-carbonitrile has potential applications in the development of drugs for different medical conditions due to its unique structure and reactivity. It can be modified and combined with other chemical entities to create new pharmaceutical compounds with specific therapeutic effects.
It is important to handle 4-bromo-1-methyl-1H-pyrrole-2-carbonitrile with care, as it may present health hazards and should be used in a controlled laboratory environment.

Upstream product

• 34884-10-1 1-methyl-1H-pyrrole-2-carbonitrile 
• 4513-94-4 1H-pyrrole-2-carbonitrile 

Downstream Products

• 1289206-26-3 5-bromo-3-(2,4-dimethylfuran-3-yl)-N'-hydroxy-4-(4-hydroxyphenyl)-1-methyl-1H-pyrrole-2-carboximidamide 
• 1289207-32-4 5-bromo-4-(4-methoxyphenyl)-1-methyl-1H-pyrrole-2-carbonitrile 
• 1289207-33-5 5-bromo-3-iodo-4-(4-methoxyphenyl)-1-methyl-1H-pyrrole-2-carbonitrile 
• 1289207-35-7 5-bromo-4-(4-hydroxyphenyl)-3-iodo-1-methyl-1H-pyrrole-2-carbonitrile 
• 1289207-36-8 5-bromo-3-(2,4-dimethylfuran-3-yl)-4-(4-hydroxyphenyl)-1-methyl-1H-pyrrole-2-carbonitrile 
• 1799628-14-0 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole-2-carbonitrile 
• 1289207-31-3 2-cyano-4-(4-methoxyphenyl)-1-methylpyrrole 

Relevant academic research and scientific papers

INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

PHOSPHATE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I): wherein X, Y, A1, A2, Ra, Rb, Rc, Rd, R3, R4, T and R5 are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, R5 and T are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

SUBSTITUTED PYRROLES AND IMIDAZOLES AS ESTROGEN RECEPTOR LIGANDS

The invention provides a compound of formula (I) wherein G is a pyrrole or imidazole moiety and R4, R5, R6, R7 are as defined in the specification; or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.